DBV技術 DBVT 深 滬
等待開盤 09-11 09:30:00 美东时间
9.52
+0.120
+1.28%
華盛通- 最 高9.54
- 今 開9.35
- 成交量 2.92万股
- 最 低 9.35
- 昨 收 9.40
- 總市值 2.60亿
- 52周最高 12.78
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 2.2045
- 委 比 0.99%
- 總股本 2734.77万
- 歷史最高 505.70
- 量 比 2.10
- 振 幅 2.02%
- 歷史最低 3.15
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IREN tops week's financial gainers, Circle Internet falls the most
This week's biggest movers among financial stocks included crypto-linked firms, fintechs and housing-related names. Overall, the Financial Select Sector SPDR ETF (XLF) dipped 1.5% in the past five ses...
09-06 22:10
DBV Technologies launches $150M ATM offering
DBV Technologies (NASDAQ:DBVT) filed a prospectus supplement with the SEC for an at-the-market offering up to $150M of American Depositary Shares. Each ADS represents five ordinary shares of the compa...
09-06 04:59
DBV Technologies Launches $150M At-The-Market Offering Program
DBV Technologies Establishes an At-The-Market (ATM) Program on NasdaqDBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage biopharmaceutical company, today announced that it has filed a prospectus supplement
09-06 04:34
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
DBV Technologies, a clinical-stage biopharmaceutical company, has announced the establishment of an at-the-market (ATM) program on the Nasdaq Capital Market, allowing it to offer and sell up to $150 million in American Depositary Shares (ADS). The proceeds will primarily support activities related to the Biologics License Application (BLA) for VIASKIN® Peanut patch in toddlers aged 1-3 years, as well as advance the development of other product ca...
09-05 20:30
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
DBV Technologies announced that CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The event will be webcast live and available on the Company’s Investors website for 90 days. DBV is developing the VIASKIN® patch for treating food allergies through epicutaneous immunotherapy, targeting millions affected by this condition. The company focuses on clinical trials...
09-03 20:30
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
DBV Technologies reported its Q2 2025 financial results, showing a net loss of $69.0 million for the first half of the year, compared to $60.5 million in 2024. Operating income decreased by $2.2 million due to reduced French research tax credits, while operating expenses rose by 7.5% due to increased R&D activities. The company raised $306.9 million in financing to advance its Viaskin Peanut patch, with $125.5 million received in April 2025. Cas...
07-29 20:08
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
DBV Technologies appoints James Briggs as Chief Human Resources Officer, succeeding Caroline Daniere. Briggs, with extensive experience in human capital and organizational transformation, will lead the company's transition from a development-stage biotech to a commercial organization. He previously served as a Partner at East Bay Human Capital and held executive roles at MNG Health, Ciox Health, and Ikaria Inc. Briggs, who holds a Master's in Hum...
07-22 20:30
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
DBV Technologies Announces It Has Screened The First Subject In COMFORT Toddlers Supplemental Safety Study In Peanut Allergic Toddlers 1 – 3 Years Old
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years OldFirst subject screened at the Respiratory Medicine Research Institute of Michigan
06-26 04:16
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
DBV Technologies has filed an addendum to its 2024 Universal Registration Document with the French financial regulator, detailing exceptional compensation granted to its CEO. The payment requires approval at the Annual Combined General Meeting on June 11. The Addendum, along with the URD, is available on DBV’s and AMF’s websites, and printed copies are accessible at DBV’s headquarters. DBV Technologies is a biopharmaceutical company developing tr...
06-03 20:30
